Michel Lotrowska, a musician and health activist in Brazil, posted this informative note on Brazil’s latest announcement that it was considering a compulsory license on patents for a medicine — in this case, efavirenz, the BMS/Merck AIDS drug marketed by… Continue Reading
On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading
Knowledge Ecology International: Q&A Session on Thai White Paper (Facts and Evidences on the 10 Burning Issues Related to the Government Use of Patents on Three Patented Essential Drugs in Thailand) Geneva, Switzerland 8 March 2007 Thiru Balasubramaniam On Thursday,… Continue Reading
March 2, 2007 Secretary of the Expert Committee on the Selection and Use of Essential Medicines (2007)Department of Medicines Policy and Standards (PSM)Health Technology & PharmaceuticalsWorld Health OrganizationCH-1211 Geneva 27Switzerland Via e-mail: emisecretariat@who.int RE: Request for changes in the WHO Model… Continue Reading
February 16, 2007 Senator Susan Collins461 Dirksen Senate Office Bldg.Washington, DC 20510 Senator Joseph Lieberman706 Hart Senate Office Bldg.Washington, DC 20510 Dear Senators, The undersigned organizations are writing to express their support for the FederalResearch Public Access Act and to… Continue Reading
The following is the text of a letter to Dr. Margaret Chan, Director-General Elect, World Health Organization (WHO), asking for a review of the Essential Drugs List (EDL) as it relates to patented products. Consumer Project on Technology http://www.cptech.org December… Continue Reading
Here is a link to the text of the WHO EB’s draft resolution on the resport of the WHO Commission on Intellectual Property, Innovation and Public Health (CIPIH). http://www.cptech.org/ip/health/who/WHOcipih280406.html from the mini EB meeting on April 28. The US government… Continue Reading
March 2006
CPTech Response to 2006 PhRMA “Special 301” Submission for Chile
The “Special 301” Report is a report that the office of the U.S. Trade Representative (USTR) submits annually to the House Ways and Means Committee and the Senate Finance Committee on the adequacy and effectiveness of intellectual property rights protection around the world. The report identifies those countries that the USTR consider “deny adequate and effective protection for IPR or deny fair and equitable market access for U.S. persons that rely on intellectual property protection”.
Original page: http://www.cptech.org/ip/wto/p6/eu12052005.pdf Letter from CPTech referenced available here: https://www.keionline.org/32641 MARKOS KYPRIANOU PETER MANDELSON Member of the European Commission … Continue Reading
This is a joint statement by that NGOs presented to negotiators in 2005, as the WTO considered an amendment on TRIPS and public health, to address cases where medicines would be exported to countries with “insufficient or no manufacturing capacity.”… Continue Reading